New combo therapy shows promise for rare, aggressive cancer

This study tests a new treatment for people with advanced high-grade neuroendocrine tumors (a rare and fast-growing cancer). The treatment combines chemotherapy (etoposide and carboplatin) with an immunotherapy drug (pembrolizumab), followed by maintenance therapy with pembrolizumab and lenvatinib. The goal is to see if this combination can shrink tumors and control the disease. The study involves up to 20 participants across 10 sites in the UK.